Although the COVID-19 pandemic continues to dominate local and global discourse in terms of research and treatment, non-communicable diseases continue to have a significant negative impact on global health. Major Non-Communicable Diseases, such as Cardiovascular Disease, Cancers, and Diabetes Mellitus continue to have a significant impact on the global population, with associated rises in terms of prevalence and mortality rates.
Whilst the treatment and prevention of COVID-19 continue to be the focus of global medical resources, significant advancements and research continue to be made in the treatment of Non-Communicable Diseases around the world, and South Africa.
Insight Survey’s latest SA Non-Communicable Diseases Landscape Report 2021, provides a synthesis of medical research, examining global and SA prevalence, current treatment, new medical research and advancements for these major Non-Communicable Diseases: Cardiovascular Diseases, Hyperlipidemia, Hypertension, Cerebrovascular Diseases, Diabetes Mellitus, Cancer, Rheumatoid Arthritis, Alzheimer’s Disease, Parkinson’s Disease.
Although COVID-19 cases and deaths remain the focus of media and medical attention, the leading non-communicable cause of death in South Africa, Diabetes Mellitus, continues to present a serious health threat to the country, with an estimated prevalence of 4.6 million cases in 2020. Additionally, according to the latest estimates, in 2019, South Africa registered the greatest number of deaths due to Diabetes Mellitus on the African continent.
Source: StatsSA Graphics by Insight Survey
Continuing global medical research and advancements are being conducted in terms of the major non-communicable diseases. These advances are being made across all of the major Non-Communicable Diseases affecting South Africa, including the likes of Diabetes Mellitus, Cerebrovascular Disease, and Cancers.
As one of the leading causes of death in South Africa, significant advancements continue to be made in the treatment of Diabetes Mellitus. Specifically, researchers at Stanford University have developed a new ultrafast insulin formulation, known as monomeric insulin. This new formulation has an almost immediate effect, working up to four times faster than current commercial insulin formulations. Further research and advances are also resulting in treatments with reduced side-effect profiles, as well as new product formats, such as Glucagon (Bagisimi). This product takes the form of a nasal powder for the treatment of severe hypoglycemia, as well as a smart insulin-delivery patch, designed for once-a-day use.
Although more difficult to treat, Cerebrovascular Disease, such as Ischaemic and Haemorrhagic Stroke, continues to see a range of significant medical advances in terms of treatment and management. As an example, AstraZeneca has developed a new medication, known as Brilinta, that can reduce the rates of stroke and death in patients previously affected by acute Ischaemic Stroke or Transient Ischaemic Attacks.
In terms of medical equipment, the FDA has approved a second-generation left atrial appendage device, Watchman FLX, which can reduce the risk of stroke, whilst offering an alternative to anticoagulant treatments. This is one of several advances in medical devices being used in the treatment and prevention of Cerebrovascular Disease.
Additionally, in terms of Cancers, significant advancements have been made across the different types of the disease. As the type of cancer with the highest local prevalence, advancements in the treatment of breast cancer are occurring rapidly. The United States Food and Drug Administration (FDA) has approved two new drugs, including Trodelvy (sacituzumab govitecan-hziy), for metastatic triple-negative breast cancer patients, as well as Tucatinib, for the treatment of HER2-positive advanced breast cancer.
An additional technological advancement includes 3-D mammography, that helps doctors screen more thoroughly for breast cancer, including in people who have no noticeable signs or symptoms. The technique may be particularly important for some females, such as those with dense breast tissue.
Some key questions the report will help you to answer:
- What are the global and South African burden of disease statistics?
- What are the definitions and characteristics of each of the major non-communicable diseases?
- What are the demographics and prevalence of each of the major non-communicable diseases?
- What treatments are currently being utilised to treat of each of the major non-communicable diseases?
- What are the latest treatments, research, and medical advancements for each of the major non-communicable diseases (including medication, medical devices, procedures, prevention, management, and cutting-edge research)?
Please note that the 150-page report is available for purchase for R27,500.00 (excluding VAT). Alternatively, individual sections can be purchased for R12,500.00 (excluding VAT). For additional information simply contact us at info@insightsurvey.co.za or directly on (021) 045-0202 or (010) 140- 5756.
For a full brochure please go to: South African Non-Communicable Diseases Report 2021
About Insight Survey:
Insight Survey is a South African B2B market research company with more than 13 years of heritage, focusing on business-to-business (B2B) and industry research to ensure smarter, more-profitable business decisions are made with reduced investment risk.
We offer B2B and industry research solutions to help you to successfully improve or expand your business, enter new markets, launch new products or better understand your internal or external environment.
Our bespoke Competitive Business Intelligence Research can help give you the edge in a global marketplace, empowering your business to overcome industry challenges quickly and effectively, and enabling you to realise your potential and achieve your vision.
From strategic overviews of your business’s competitive environment through to specific competitor profiles, our customised Competitive Intelligence Research is designed to meet your unique needs.
For more information, go to www.insightsurvey.co.za.